MBC

MasterBrand Reports First Quarter 2024 Financial Results

Retrieved on: 
Mardi, mai 7, 2024
Manufacturing, Interior Design, Other Manufacturing, Residential Building & Real Estate, Construction & Property, Depreciation, Webcast, Forecasting, Public expenditure, Tax, EPS, Lead, MBC, GAAP, Bank

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced first quarter 2024 financial results.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced first quarter 2024 financial results.
  • “We delivered a solid quarter of results to start the year, with continued year-over-year adjusted EBITDA margin expansion and strong first quarter free cash flow,” said Dave Banyard, President and Chief Executive Officer.
  • “With our first quarter financial and operational performance in line with our expectations, we are reiterating our full year 2024 outlook provided on February 26, 2024,” said Andi Simon, Executive Vice President and Chief Financial Officer.
  • ET today, May 7, 2024, to discuss the financial results and business outlook.

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

Retrieved on: 
Lundi, mai 6, 2024
Frustration, Tardive dyskinesia, Neurocrine Biosciences, Risk, Mental Health Awareness Month, Neurocrine, Bipolar disorder, DSM-IV codes, Somatic symptom disorder, Schizophrenia, Policy, Mental health, Patient, Movement disorder, Diagnosis, MBC, Mental, SAN, Nursing

SAN DIEGO, May 6, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11.

Key Points: 
  • SAN DIEGO, May 6, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11.
  • "TD Awareness Week increases dialogue around the physical, social and emotional consequences the uncontrollable movements of TD can have on individuals who are trying to manage their mental health," said Josie Cooper, Executive Director of the Movement Disorders Policy Coalition.
  • "We are committed to partnering with all stakeholders during TD Awareness Week and beyond to advocate for routine screenings for patients at risk for TD."
  • To learn more about TD, living with TD and how to treat TD, visit TalkAboutTD.com .

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
Vendredi, mai 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
Vendredi, mai 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

ONO PHARMA USA Announces 2024 Golden Ticket Competition Now Accepting Applications from Innovative Startups

Retrieved on: 
Jeudi, mai 2, 2024
Immunology, Golden Ticket, ONO, Patient, Neurology, MBC, Kendall Square, The Golden Ticket, LabCentral, Organization

CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company. The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.

Key Points: 
  • CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company.
  • The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.
  • The Golden Ticket awards provide two promising early-stage R&D companies lab space and mentorship, components that are vital to the success of promising life science businesses.
  • The competition seeks proposals from startup companies in the oncology, immunology, neurology, and specialty areas.

Mental Health Outcomes Demonstrate the Swift and Significant Impact of TimelyCare

Retrieved on: 
Mercredi, mai 1, 2024
Education, Risk, PHQ-9, LMFT, Depression, Grammatical mood, Patient Health Questionnaire, Attention, Patient safety, Senior counsel, Psychiatry, GPA, Mental health, Movement, Faculty, GAD-7, MBC, Evidence-based practice, Student, Nursing

FORT WORTH, Texas, May 1, 2024 /PRNewswire/ -- TimelyCare, higher education's most trusted virtual health and well-being provider, is swiftly and significantly improving the mental health of those who need support the most. This is highly important given mental health is the #1 reason students drop out of college.

Key Points: 
  • This is highly important given mental health is the #1 reason students drop out of college.
  • TimelyCare began using Measurement-Based Care (MBC) last year, an evidence-based practice of tracking patient-reported progress in real-time to enhance treatment outcomes.
  • TimelyCare practitioners started collecting Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder Assessment (GAD-7) scores prior to Scheduled Counseling and Psychiatry visits.
  • "The TimelyCare MBC data underscore the correlation between improved mental health outcomes and student success," said Bob Booth, M.D., TimelyCare's Chief Care Officer.

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

Retrieved on: 
Mardi, avril 30, 2024
FDA, Pancreatic cancer, News, Breast, Fulvestrant, Fast track (FDA), ONC, MBC, PFE, Classification, ICE3, Breast cancer, Paclitaxel, Learning, Kidney, Woman, Economics, Hand, Traction, TSX, Optimism, Eli Lilly and Company, Patient satisfaction, Proteolysis, Freezing, Survival, NEO, Marketing, Clinical trial, CDK, University, Progression-free survival, Recurrence, Disease, Chimera, Patient, Liver, Neoplasm, Type, Growth, Pharmaceutical industry

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism towards new treatments, and significant growth of 9.3% CAGR in the metastatic HR+/HER2- breast cancer market through 2032 has treatment developers working harder to make gains for patients. Among the biotech companies currently making strides are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), IceCure Medical Ltd (NASDAQ: ICCM), Atossa Therapeutics, Inc. (NASDAQ: ATOS), Arvinas, Inc. (NASDAQ: ARVN), and Pfizer Inc. (NYSE: PFE) (NEO: PFE).

Key Points: 
  • Recently, Oncolytics announced that they had submitted a Type C meeting request to the FDA to discuss a forthcoming trial for pelareorep aimed at treating HR+/HER2- metastatic breast cancer (mBC) patients.
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • The company looks forward to meeting with the FDA in Q2 2024 to finalize the trial design and goals for using pelareorep in treating metastatic breast cancer.

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

Retrieved on: 
Mardi, avril 30, 2024
FDA, Pancreatic cancer, News, Breast, Fulvestrant, Fast track (FDA), ONC, MBC, PFE, Classification, ICE3, Breast cancer, Paclitaxel, Learning, Kidney, Woman, Economics, Hand, Traction, TSX, Optimism, Eli Lilly and Company, Patient satisfaction, Proteolysis, Freezing, Survival, NEO, Marketing, Clinical trial, CDK, University, Progression-free survival, Recurrence, Disease, Chimera, Patient, Liver, Neoplasm, Type, Growth, Pharmaceutical industry

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism towards new treatments, and significant growth of 9.3% CAGR in the metastatic HR+/HER2- breast cancer market through 2032 has treatment developers working harder to make gains for patients. Among the biotech companies currently making strides are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), IceCure Medical Ltd (NASDAQ: ICCM), Atossa Therapeutics, Inc. (NASDAQ: ATOS), Arvinas, Inc. (NASDAQ: ARVN), and Pfizer Inc. (NYSE: PFE) (NEO: PFE).

Key Points: 
  • Recently, Oncolytics announced that they had submitted a Type C meeting request to the FDA to discuss a forthcoming trial for pelareorep aimed at treating HR+/HER2- metastatic breast cancer (mBC) patients.
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • The company looks forward to meeting with the FDA in Q2 2024 to finalize the trial design and goals for using pelareorep in treating metastatic breast cancer.

Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024

Retrieved on: 
Vendredi, avril 19, 2024
Mutation, MBC, KOL, Therapy, Patient, Neoplasm, Harvard Medical School, MD Anderson Cancer Center, Massachusetts General Hospital, Breast cancer, ESR1, Pharmaceutical industry

COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today announced it will host a virtual KOL fireside chat on Monday, April 22, 2024 from noon to 1 p.m.

Key Points: 
  • COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today announced it will host a virtual KOL fireside chat on Monday, April 22, 2024 from noon to 1 p.m.
  • ET, featuring Senthil Damodaran, M.D., Ph.D. (MD Anderson Cancer Center) and Seth Wander, M.D., Ph.D. (Harvard Medical School, Massachusetts General Hospital) to discuss the unmet need and current treatment landscape for metastatic breast cancer.
  • The event will focus on the company's ELAINE (Evaluating Lasofoxifene in ESR1 Mutations) studies investigating lasofoxifene in patients with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer expressing an estrogen receptor 1 (ESR1) mutation.
  • A live question and answer session will follow the formal presentations.

Osmind Announces Collaboration with the American Psychiatric Association to Advance Quality Psychiatric Care and Accelerate Research

Retrieved on: 
Jeudi, mai 2, 2024
Software, Practice Management, General Health, Health, Mental Health, Data Management, Health Technology, Technology, APA, Education, RWE, American Psychiatric Association, Psychiatry, Private practice, EHR, MD, Collection, Automation, Patient, MBC, Medicine, Nursing

Today, Osmind , the leading psychiatric treatment and research platform, announced an innovative collaboration with the American Psychiatric Association (APA) to improve the adoption of measurement-based care (MBC) and precision treatment in psychiatry.

Key Points: 
  • Today, Osmind , the leading psychiatric treatment and research platform, announced an innovative collaboration with the American Psychiatric Association (APA) to improve the adoption of measurement-based care (MBC) and precision treatment in psychiatry.
  • This collaboration between Osmind and APA’s PsychPRO registry intends to broaden access to personalized care, improve patient outcomes, generate robust real-world evidence (RWE) and accelerate psychiatry’s evolution to precision medicine.
  • PsychPRO registry is a clinical data registry that enables the collection and analysis of clinical data to advance quality improvement efforts and accelerate research for the psychiatric community.
  • Through this collaboration, Osmind is enabling independent practices to contribute to the evolution of the field and elevate their own evidence-based practices.